Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on January 4, 2007

Stroke. 2007
Published online before print January 4, 2007, doi: 10.1161/01.STR.0000254462.75851.22
A more recent version of this article appeared on February 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/2/388    most recent
01.STR.0000254462.75851.22v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sena, E.
Right arrow Articles by Macleod, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sena, E.
Right arrow Articles by Macleod, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Animal models of human disease
Right arrowRelated Article

Submitted on May 1, 2006
Revised on June 23, 2006
Accepted on July 17, 2006

Systematic Review and Meta-Analysis of the Efficacy of Tirilazad in Experimental Stroke

Emily Sena BSc; Philippa Wheble BSc; Peter Sandercock MD; and Malcolm Macleod PhD*

From Clinical Neurosciences, University of Edinburgh, Scotland.

* To whom correspondence should be addressed. E-mail: malcolm{at}apoptosis.freeserve.co.uk.

Background and Purpose--Tirilazad is a candidate neuroprotective drug with reported efficacy in animal models of stroke that was, however, without benefit in clinical trials. This apparent contradiction might be explained if the animal studies were falsely positive, if the clinical trials were falsely negative, or if tirilazad was not tested under the same conditions in animal and clinical studies. Here we use systematic review and meta-analysis to describe the characteristics and limits to the neuroprotective action of tirilazad in animal models of stroke.

Methods--Systematic review and meta-analysis of studies describing the efficacy of tirilazad in animal models of focal ischemia, in which outcome was measured as infarct volume and/or neurological score. Weighted mean difference random effects meta-analysis was used to measure overall efficacy in prespecified subgroups.

Results--Eighteen studies describing outcome in 544 animals were identified. Study quality (median score, 5/10; interquartile range, 4 to 6) was similar to that seen in systematic reviews of other candidate neuroprotective drugs. Tirilazad reduced infarct volume by 29.2% (95% confidence interval 21.1% to 37.2%) and improved neurobehavioral score by 48.1% (95% confidence interval 29.3% to 66.9%).

Conclusion--Tirilazad may have substantial efficacy in animal models of stroke, but this conclusion must be qualified because of the presence of potential sources of bias.


Related Article:

The Thr715Pro Polymorphism of the P-Selectin Gene Is Not Associated With Ischemic Stroke Risk
Julia Ferrari, Sandra Rieger, Georg Endler, Stefan Greisenegger, Marion Funk, Thomas Scholze, Wilfried Lang, Wolfgang Lalouschek, and Christine Mannhalter
Stroke 2007 38: 395-397. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
StrokeHome page
M. R. Macleod, H. B. van der Worp, E. S. Sena, D. W. Howells, U. Dirnagl, and G. A. Donnan
Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality
Stroke, October 1, 2008; 39(10): 2824 - 2829.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Minnerup, J. Heidrich, J. Wellmann, A. Rogalewski, A. Schneider, and W.-R. Schabitz
Meta-Analysis of the Efficacy of Granulocyte-Colony Stimulating Factor in Animal Models of Focal Cerebral Ischemia
Stroke, June 1, 2008; 39(6): 1855 - 1861.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
N. A. Crossley, E. Sena, J. Goehler, J. Horn, B. van der Worp, P. M.W. Bath, M. Macleod, and U. Dirnagl
Empirical Evidence of Bias in the Design of Experimental Stroke Studies: A Metaepidemiologic Approach
Stroke, March 1, 2008; 39(3): 929 - 934.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
C. L. Gibson, L. J. Gray, P. M. W. Bath, and S. P. Murphy
Progesterone for the treatment of experimental brain injury; a systematic review
Brain, February 1, 2008; 131(2): 318 - 328.
[Abstract] [Full Text] [PDF]